AAAAAA

   
Results: 1-15 |
Results: 15
ANTIRETROVIRAL THERAPY - WHERE ARE WE GOING - FACULTY ROUND-TABLE DISCUSSION
Authors: FROST KR SAAG M CURRIER J COHEN CJ MERRICK S LEONARD A DOBKIN J ELSADR W HOLODNIY M BELLMAN P VAUGHN A RUBIN DS PINSKY L
Citation: Kr. Frost et al., ANTIRETROVIRAL THERAPY - WHERE ARE WE GOING - FACULTY ROUND-TABLE DISCUSSION, AIDS patient care and STDs, 12(7), 1998, pp. 543-555
ANTIRETROVIRAL THERAPY - WHERE ARE WE GOING - QUESTION AND ANSWER SESSION
Authors: CURRIER J FROST KR RUBIN D ELSADR W BELLMAN P COHEN CJ MERRICK S DOBKIN J SAAG M VAUGHN A LEONARD A
Citation: J. Currier et al., ANTIRETROVIRAL THERAPY - WHERE ARE WE GOING - QUESTION AND ANSWER SESSION, AIDS patient care and STDs, 12(7), 1998, pp. 557-566
ANALYSIS OF LYMPH-NODE BIOPSIES IN HIV-INFECTED PATIENTS BEFORE AND AFTER HAART
Authors: BUCY RP KILBY JM DERDEYN CA HORTON D SILLERS M SQUIRES K SAAG M SHAW GM HOCKETT RD
Citation: Rp. Bucy et al., ANALYSIS OF LYMPH-NODE BIOPSIES IN HIV-INFECTED PATIENTS BEFORE AND AFTER HAART, The FASEB journal, 12(4), 1998, pp. 1719-1719
REPORT OF THE NIH PANEL TO DEFINE PRINCIPLES OF THERAPY OF HIV-INFECTION
Authors: CARPENTER C FEINBERG M AUBRY W AVERITT D COFFIN J COOPER D FOLLANSBEE S HAMBURG P HARRINGTON M HIDALGO J JAFFE H LANDERS D MASUR H PIZZO P RICHMAN D SAAG M SCHOOLEY R STONE V THOMPSON M TRONO D VELLA S WALKER B YENI P
Citation: C. Carpenter et al., REPORT OF THE NIH PANEL TO DEFINE PRINCIPLES OF THERAPY OF HIV-INFECTION, Annals of internal medicine, 128(12), 1998, pp. 1057-1078
POLYOL-COMBINANT SALIVA STIMULANTS - A 4-MONTH PILOT-STUDY IN YOUNG-ADULTS
Authors: MAKINEN KK OLAK J RUSSAK S SAAG M SEEDRE T VASAR R VIHALEMM T MIKELSAAR M MAKINEN PL
Citation: Kk. Makinen et al., POLYOL-COMBINANT SALIVA STIMULANTS - A 4-MONTH PILOT-STUDY IN YOUNG-ADULTS, Acta Odontologica Scandinavica, 56(2), 1998, pp. 90-94
SAFETY AND ANTIVIRAL ACTIVITY OF COMBINATION THERAPY WITH ZIDOVUDINE,ZALCITABINE, AND 2 DOSES OF INTERFERON-ALPHA(2A) IN PATIENTS WITH HIV- AIDS CLINICAL-TRIALS GROUP-STUDY-197
Authors: FISCHL MA RICHMAN DD SAAG M MENG TC SQUIRES KE HOLDENWILTSE J MEEHAN PM
Citation: Ma. Fischl et al., SAFETY AND ANTIVIRAL ACTIVITY OF COMBINATION THERAPY WITH ZIDOVUDINE,ZALCITABINE, AND 2 DOSES OF INTERFERON-ALPHA(2A) IN PATIENTS WITH HIV- AIDS CLINICAL-TRIALS GROUP-STUDY-197, Journal of acquired immune deficiency syndromes and human retrovirology, 16(4), 1997, pp. 247-253
ITRACONAZOLE ORAL SOLUTION - PHARMACOKINETICS AND ABSORPTION
Authors: SAAG M
Citation: M. Saag, ITRACONAZOLE ORAL SOLUTION - PHARMACOKINETICS AND ABSORPTION, AIDS patient care, 11, 1997, pp. 16-17
TREATMENT OF HISTOPLASMOSIS WITH FLUCONAZOLE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME
Authors: WHEAT J MAWHINNEY S HAFNER R MCKINSEY D CHEN DF KORZUN A SHAKAN KJ JOHNSON P HAMILL R BAMBERGER D PAPPAS P STANSELL J KOLETAR S SQUIRES K LARSEN RA CHEUNG T HYSLOP N LAI KK SCHNEIDER D KAUFFMAN C SAAG M DISMUKES W POWDERLY W
Citation: J. Wheat et al., TREATMENT OF HISTOPLASMOSIS WITH FLUCONAZOLE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME, The American journal of medicine, 103(3), 1997, pp. 223-232
THE SAFETY AND ANTIVIRAL EFFECT OF 1592U89, ALONE AND IN COMBINATION WITH ZIDOVUDINE IN HIV-1-INFECTED PATIENTS WITH CD4-500 CELLS( COUNTS 200)MM(3)/
Authors: SONNERBORG A LANCASTER D TORRES R THOMPSON M SAAG M SCHOOLEY R MULDER J GAZZARD B DAQUILA R GURGUL M FEINBERG J SANTIN M LANG W HARRIGAN PR STEEL H TORTELL S ROMERO C
Citation: A. Sonnerborg et al., THE SAFETY AND ANTIVIRAL EFFECT OF 1592U89, ALONE AND IN COMBINATION WITH ZIDOVUDINE IN HIV-1-INFECTED PATIENTS WITH CD4-500 CELLS( COUNTS 200)MM(3)/, AIDS, 10, 1996, pp. 41-41
QUANTITATIVE-ANALYSIS OF REPLICATION-ACTIVE, LATENT, AND DEFECTIVE FORMS OF HIV-1 PROVIRUS IN PERIPHERAL-BLOOD - IMPLICATIONS FOR VIRAL PATHOGENESIS AND THERAPY
Authors: TAYLOR R GERMANYDECKER J WEI X LIFSON J NOWAK M SAAG M HAHN B SHAW G
Citation: R. Taylor et al., QUANTITATIVE-ANALYSIS OF REPLICATION-ACTIVE, LATENT, AND DEFECTIVE FORMS OF HIV-1 PROVIRUS IN PERIPHERAL-BLOOD - IMPLICATIONS FOR VIRAL PATHOGENESIS AND THERAPY, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 78-78
VIRAL DYNAMICS IN HIV-1 INFECTION
Authors: SHAW G WEI X GHOSH S JOHNSON V DEUTSCH P EMMINI E LIFSON J NOWAK M HAHN B SAAG M
Citation: G. Shaw et al., VIRAL DYNAMICS IN HIV-1 INFECTION, Journal of cellular biochemistry, 1995, pp. 181-181
CONSENSUS CONFERENCE ON LABORATORY MARKERS IN HIV-INFECTION - CONSENSUS CONCLUSIONS
Authors: AIUTI F BOUCHER C DIANZANI F FENYO EM HO D LANE C LANGE J MONTANER J PANTALEO G PERRIN L ROMAGNANI S SAAG M SCHOOLEY R VELLA S
Citation: F. Aiuti et al., CONSENSUS CONFERENCE ON LABORATORY MARKERS IN HIV-INFECTION - CONSENSUS CONCLUSIONS, Journal of biological regulators and homeostatic agents, 9(3), 1995, pp. 119-120
A PRELIMINARY-STUDY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE, TO TREAT HIV-1 INFECTION
Authors: MARKOWITZ M SAAG M POWDERLY WG HURLEY AM HSU A VALDES JM HENRY D SATTLER F LAMARCA A LEONARD JM HO DD
Citation: M. Markowitz et al., A PRELIMINARY-STUDY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE, TO TREAT HIV-1 INFECTION, The New England journal of medicine, 333(23), 1995, pp. 1534-1539
PHARMACOKINETICS OF L-735,524, AN HIV PROTEASE INHIBITOR
Authors: TEPPLER H OSBORNE B BJORNSSON TD POMERANTZ R WOOLF E YEH K DEUTSCH P SQUIRES K SAAG M
Citation: H. Teppler et al., PHARMACOKINETICS OF L-735,524, AN HIV PROTEASE INHIBITOR, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 195-195
IMPLICATIONS OF PERSISTENT PLASMA VIREMIA IN ACUTE AND EARLY-CHRONIC INFECTION IN HIV-1 NATURAL-HISTORY AND PATHOGENESIS
Authors: SHAW G SAAG M CLARK S KAPPES J HAHN B YANG LM LUK KC PIATAK M LIFSON J
Citation: G. Shaw et al., IMPLICATIONS OF PERSISTENT PLASMA VIREMIA IN ACUTE AND EARLY-CHRONIC INFECTION IN HIV-1 NATURAL-HISTORY AND PATHOGENESIS, Journal of cellular biochemistry, 1993, pp. 3-3
Risultati: 1-15 |